Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

The company s next-generation shot surpassed Wall Street s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.